Product image of Levodopa/Carbidopa/Entacapone Stada Arzneimittel Ag (Carbidopa, Entacapone, Levodopa) supplied by GNH India

Levodopa/Carbidopa/Entacapone Stada Arzneimittel Ag

Active Ingredient:
Carbidopa, Entacapone, Levodopa
Origin:
EU

Levodopa/Carbidopa/Entacapone Stada Arzneimittel Ag (Carbidopa, Entacapone, Levodopa)

Levodopa, carbidopa, entacapone, the active ingredients in Levodopa/Carbidopa/Entacapone Stada Arzneimittel Ag, constitute a combination dopamine precursor therapy presented as an oral tablet for oral administration. The formulation is indicated for the management of Parkinson's disease and associated motor fluctuations in adult patients.

GNH India supplies Levodopa/Carbidopa/Entacapone Stada Arzneimittel Ag as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality standards. The company adheres to EU GMP guidelines and offers logistical support for customs clearance and temperature‑controlled shipping where required.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Levodopa/Carbidopa/Entacapone is used in the dopaminergic pathway to manage Parkinsonian disorders.

  • Parkinson's disease: improves overall motor function and reduces rigidity and bradykinesia.
  • Parkinson's disease motor fluctuations: decreases OFF periods and prolongs ON time without troublesome dyskinesia.
  • Parkinson's disease with wearing‑off phenomenon: stabilizes dopamine levels to smooth symptom control.

How It Works

  • Levodopa crosses the blood‑brain barrier and is decarboxylated to dopamine, restoring deficient central neurotransmission. Carbidopa inhibits peripheral aromatic L‑amino‑acid decarboxylase, preventing premature conversion of levodopa and increasing its cerebral availability while reducing peripheral side effects. Entacapone blocks catechol‑O‑methyltransferase (COMT) in the periphery, slowing levodopa metabolism, extending its plasma half‑life and enhancing the duration of dopaminergic stimulation.

Side Effects

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

  • Nausea
  • Vomiting
  • Dizziness
  • Orthostatic hypotension
  • Insomnia
  • Dry mouth

Serious or Rare Side Effects

  • Dyskinesia
  • Neuroleptic malignant syndrome
  • Severe hypotension
  • Hallucinations or psychosis
  • Anaphylactic or severe allergic reactions

Precautions & Warnings

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should observe several safety measures.

  • Blood pressure monitoring: check for orthostatic changes especially after dose initiation.
  • Psychiatric assessment: observe for hallucinations, confusion or mood changes.
  • Renal function evaluation: adjust dosing in severe impairment.
  • Hepatic function: monitor liver enzymes due to entacapone metabolism.
  • Hypersensitivity: discontinue if rash or angioedema occurs.
  • Store at room temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Levodopa/Carbidopa/Entacapone interacts with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

  • Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis.
  • Antipsychotics (e.g., haloperidol, risperidone): may diminish antiparkinson effect.
  • Other COMT inhibitors: additive toxicity.

Moderate Interactions (Monitor Closely)

  • SSRIs and SNRIs: may increase risk of serotonin syndrome.
  • Antihypertensive agents: additive blood‑pressure lowering.
  • Iron or levodopa‑containing dietary supplements: reduce levodopa absorption.
  • Anticholinergic drugs: may enhance central side effects.

Frequently Asked Questions

Levodopa/Carbidopa/Entacapone is prescribed to treat Parkinson's disease and to manage motor fluctuations such as OFF periods. It helps improve motor symptoms like rigidity, tremor, and bradykinesia by restoring dopamine levels in the brain.

The combination works on three levels: levodopa is converted to dopamine in the brain, carbidopa blocks peripheral conversion of levodopa to reduce side effects and increase central availability, and entacapone inhibits the COMT enzyme, prolonging levodopa’s plasma half‑life and enhancing its therapeutic effect.

Dosage is individualized and set by the prescribing clinician based on the patient’s disease severity, response to therapy, age, renal and hepatic function, and concomitant medications. No standard dose can be provided without a medical assessment.

Safety data in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless absolutely necessary.

Enquiries are submitted via the product page on gnhindia.com where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Standard levodopa/carbidopa provides dopamine replacement but has a shorter plasma half‑life, leading to more frequent dosing and motor fluctuations. Adding entacapone extends levodopa’s duration of action, reduces OFF time, and may allow fewer daily doses, offering smoother symptom control.

Store the tablets at room temperature, preferably below 25 °C, in the original blister pack or container. Protect them from excessive moisture, heat and direct sunlight to maintain potency throughout the shelf life.

The medication is taken orally, usually with food or a light snack to reduce gastrointestinal irritation. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious adverse events include dyskinesia, neuroleptic malignant syndrome, severe hypotension, hallucinations or psychosis, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if any of these symptoms develop.

Individuals with known hypersensitivity to levodopa, carbidopa, entacapone or any excipients should avoid the product. It is also contraindicated in patients taking non‑selective MAO inhibitors and those with severe hepatic impairment without careful medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Carbidopa, Entacapone, Levodopa

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT